Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose Response Curve: Conventional Versus Nonmonotonic01:21

Dose Response Curve: Conventional Versus Nonmonotonic

187
The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response...
187
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

334
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
334
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

5.7K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.7K
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

311
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
311
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

437
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
437
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

7.1K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
7.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Testing of evaluation bias for progression free survival endpoint in oncology clinical trials.

Statistics in medicine·2016
Same author

New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study.

Statistics in medicine·2016
Same author

Concept-Based Word Learning in Human Infants.

Psychological science·2015
Same author

Vitexin reduces hypoxia-ischemia neonatal brain injury by the inhibition of HIF-1alpha in a rat pup model.

Neuropharmacology·2015
Same author

Visible-Light-Dependent Photocyclization: Design, Synthesis, and Properties of a Cyanine-Based Dithienylethene.

The Journal of organic chemistry·2015
Same author

Salvianolic acid A inhibits endothelial dysfunction and vascular remodeling in spontaneously hypertensive rats.

Life sciences·2015

Related Experiment Video

Updated: Mar 15, 2026

Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine
08:33

Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine

Published on: July 24, 2018

11.9K

A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.

Jun Yin1, Rui Qin1, Monia Ezzalfani2

  • 1Department of Health Sciences Research, Mayo Clinic, 55905, Rochester, MN, U.S.A.

Statistics in Medicine
|September 17, 2016
PubMed
Summary

This study introduces a new method for Phase I oncology trials to better assess cumulative toxicity over multiple cycles. The repeated measures design improves dose-finding accuracy compared to traditional methods using only early data.

Keywords:
continuous endpointlate and cumulative toxicitylongitudinalmolecularly targeted agentoncologyphase I

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K
Topical Application Bioassay to Quantify Insecticide Toxicity for Mosquitoes and Fruit Flies
09:37

Topical Application Bioassay to Quantify Insecticide Toxicity for Mosquitoes and Fruit Flies

Published on: January 19, 2022

7.3K

Related Experiment Videos

Last Updated: Mar 15, 2026

Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine
08:33

Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine

Published on: July 24, 2018

11.9K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K
Topical Application Bioassay to Quantify Insecticide Toxicity for Mosquitoes and Fruit Flies
09:37

Topical Application Bioassay to Quantify Insecticide Toxicity for Mosquitoes and Fruit Flies

Published on: January 19, 2022

7.3K

Area of Science:

  • Oncology
  • Clinical Trials
  • Biostatistics

Background:

  • Phase I oncology trials aim to find safe drug doses based on toxicity.
  • Current methods often simplify complex toxicity data into a single outcome.
  • Existing dose-finding designs may not fully capture cumulative toxicity over treatment cycles.

Purpose of the Study:

  • To propose a novel statistical design for Phase I oncology trials.
  • To incorporate longitudinal repeated measures of total toxicity profile over multiple cycles.
  • To account for cumulative toxicity during the dose-finding process.

Main Methods:

  • Utilized a linear mixed model within a Bayesian framework.
  • Incorporated Bayesian risk functions for dose assignment decisions.
  • Compared the proposed design with the quasi-likelihood continual reassessment method (QLCRM) using simulation studies.

Main Results:

  • The proposed repeated measures design showed comparable performance to QLCRM when using only cycle 1 data.
  • The new design demonstrated significant improvement over QLCRM when utilizing data from multiple cycles.
  • Performance was evaluated across twelve clinical scenarios with varying maximum tolerated dose locations and time trends.

Conclusions:

  • The proposed longitudinal repeated measures design offers an improved approach to dose-finding in Phase I oncology trials.
  • Accounting for cumulative toxicity over multiple cycles enhances the accuracy of dose selection.
  • This method provides a more comprehensive assessment of toxicity profiles for safer drug development.